pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 44 Non-oncology: 29
Oncology: 15
Under Consideration for Negotiation 12 Non-oncology: 8
Oncology: 4
Completed Negotiations 787 With Letter of Intent: 680
Without agreement: 107
Negotiations That Were Not Pursued 108

pCPA activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement letters issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Ebglyss Eli Lilly Canada Inc. Atopic dermatitis
Zilbrysq UCB Canada Inc. Generalized myasthenia gravis (gMG)
Leqvio Novartis Pharmaceuticals Canada Inc. Primary hypercholesterolemia (non-familial and heterozygous familial)
Winrevair Merck Canada Inc. Pulmonary Arterial Hypertension (WHO group 1)
Leqvio Novartis Pharmaceuticals Canada Inc. Primary hypercholesterolemia
Vyloy Astellas Pharma Inc. In combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal

Negotiations completed in the last four weeks with a letter of intent

Brand Name Manufacturer Indication Engagement Date Close Date
Enhertu (concluded with pTAP LOI) AstraZeneca Canada Inc. As monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti-HER2-based regimen
Nextstellis Searchlight Pharma Inc. Prevention of Pregnancy
Trodelvy Gilead Sciences Canada Inc. Breast cancer, unresectable locally advanced or metastatic, HR-positive, HER2-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) in adult patients who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting
Tecvayli Janssen Inc. Multiple myeloma, relapsed or refractory, in adult patients who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progre
Cabtreo Bausch Health, Canada Inc. Acne Vulgaris
Xcopri Paladin Labs Inc. Epilepsy, partial-onset seizures

Negotiations completed in the last four weeks without agreement

Brand Name Manufacturer Indication Engagement Date Close Date
Beqvez Pfizer Canada ULC Hemophilia B (congenital Factor IX deficiency) in adults (aged 18 years or older), moderately severe to severe, who are negative for neutralizing antibodies to variant AAV serotype Rh74

Negotiations that pCPA decided not to pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks